Skip to main content
. 2017 Oct 27;22(12):1444–1450. doi: 10.1634/theoncologist.2016-0488

Figure 2.

image

A series of positron emission tomography scans showing a robust and sustained response to a crizotinib‐based treatment regimen. The patient received cervical radiotherapy, one cycle of chemotherapy (cytoxan 750 mg/m2, etoposide 100 mg/m2 days 1–3, and prednisone 100 mg days 1–5), and crizotinib 250 mg daily from July 2015 to present. Shown here are scans taken prior to treatment initiation (far left) and at 20 weeks (center) and 35 weeks (right) after treatment initiation.